The biomarkers that predict the efficacy of ICB therapy include the expression of programmed death-ligand 1 (PD-L1) (Nishino et al., 2017), tumor mutation load (Snyder et al., 2014), mismatch repair deficiency (Le et al., 2015), and gut microbiota (Daillère et al., 2016; Routy et al., 2018). This evidence concerns the gene CD274 and neoplasm.